Phase I study of Gliadel™ wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas

Neuro-Oncology

Volumn 3, Issue 4, 2001, Pages 246-250

  Gururangan, Sridharan ^a   Cokgor, Ilkcan ^a   Rich, Jeremy N ^a   Edwards, Shari ^a   Affronti, Mary Lou ^a   Quinn, Jennifer A ^a   Herndon II, James E ^a   Provenzale, James M ^a   McLendon, Roger E ^a   Tourt Uhlig, Sandra ^a   Sampson, John H ^a   Stafford Fox, Valerie ^b   Zaknoen, Sara ^b   Early, Maureen ^c   Friedman, Alan H ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Aventis Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG IMPLANT; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SAFETY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; CARMUSTINE; COHORT STUDIES; DACARBAZINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SAFETY; SUPRATENTORIAL NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 18044402671     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1522851700000703     Document Type: Article

References (24)

1. Belanich, M., Pastor, M., Randall, T., and Guerra, D., Kibitel, J., Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K., Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D. (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56, 783-788.
2. Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S.C., for the Polymer-Brain Tumor Treatment Group (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008-1012.
3. Chang, C.H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J.S., and Tsukada, Y. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group Study. Cancer 52, 997-1007.
4. 6-benzylguanine and its role in chemotherapy. Clin. Cancer Res. 3, 837-847.
5. Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20, 111-120.
6. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., and Schold, S.C., Jr. (1992) Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst. 84, 1926-1931.
7. Friedman, H.S., Johnson, S.P., Dong, Q., Schold, S.C., Rasheed, B.K., Bigner, S.H., Ali-Osman, F., Dolan, E., Colvin, O.M., Houghton, R, Germain, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P. (1997) Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 57, 2933-2936.
8. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16, 3851-3857.
9. Grossman, S.A., Reinhard, C., Colvin, O.M., Chasin, M., Brundrett, R., Tamargo, R.J., and Brem, H. (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76, 640-647.
10. Hammond, L.A., Eckardt, J.R., Baker, S.D., Eckhardt, S.G., Dugan, M., Forral, K., Reidenberg, P., Statkevich, P., Weiss, G.R., Rinaldi, D.A., Von Hoff, D.D., and Rowinsky, E.K. (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5 days schedule in patients with advanced solid malignancies. J. Clin. Oncol. 17, 2604-2613.
11. Horspool, K.R., Stevens, M.F., Newton, C.G., Lunt, E., Walsh, R.J., Pedgrift, B.L., Baig, G.U., Lavelle, F., and Fizames, C. (1990) Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents. J. Med. Chem. 33, 1393-1399.
12. 6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J. Neurooncol. 21, 135-140.
13. 6-methylguanine-DNA methyl transferase levels with survival of malignant astrocytoma in patients treated with bis-chloroethylnitrosourea. A Southwest Oncology Group study. J. Clin. Oncol. 16, 3310-3315.
14. Lage, H., and Dietel, M. (1999) Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 125, 156-165.
15. Liu, L., Markowitz, S., and Gerson, S.L. (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chlorethyl) nitrosourea. Cancer Res. 56, 5375-5379.
16. Ludlum, D.B. (1990) DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat. Res. 233, 117-126.
17. Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., Hoffman, R., Stevens, M.F., and Brampton, M.H. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856). Br. J. Cancer 65, 287-291.
18. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50, 6119-6129.
19. Plowman, J., Waud, W.R., Koutsoukos, A.D., Rubinstein, L.V., Moore, T.D., and Grever, M.R. (1994) Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54, 3793-3799.
20. Schold, S.C., Jr., Kuhn, J.G., Chang, S.M., Bosik, M.E., Robins, H.I., Mehta, M.P., Spence, A.M., Fulton, D., Fink, K.L. and Prados, M.D. (2000) A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide. A North American Brain Tumor Consortium study. Neuro-Oncology [serial online], Doc. 99-26, December 9, 1999. URL http://neuro-oncology.mc. duke.edu. Neuro-Oncol. 2, 34-39.
21. Walker, M.D., Green, S.B., Byar, D.P., Alexander, E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Owens. G., Ransohoff, J., II, Robertson, J.T., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1980) Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323-1329.
22. 6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer 74, 1030-1036.
23. Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 17, 2762-2771.
24. Yung, W.K.A., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada. M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multi-forme at first relapse. Br. J. Cancer 83, 588-593.